目的 探讨无症状感染者在新冠肺炎家庭聚集性疫情中的传播风险,分析家庭聚集性疫情中所有患者的住院治疗情况,为防控策略和治疗方案制定提供依据。方法 通过现场流行病学调查获得旅居史和暴露危险因素,并收集临床治疗资料,利用统计软件进行作图和分析。结果 指示病例的潜伏期为15天,其余4名家庭成员的潜伏期为1～15天,其中指示病例作为无症状感染者,在感染后第4～6天内具有传染性相继导致4名成员感染;指示病例携带病毒8天以上,其余4人从2天到31天不等; 症状持续时间5~20天,住院期间共进行CT检查次数为4～10次,肺部炎症最快在住院第三天好转。发病初期只有1个病例出现白细胞、淋巴细胞降低。发病到就诊和住院的时间间隔为1～10天,平均住院时间为23.4天。结论 无症状感染者在家庭聚集性疫情传播中具有关键作用,难以及时发现,存在较大传播风险,为新冠肺炎疫情防控带来较大难度。

Objective To study the transmission risk of asymptomatic patient in a family-clustered outbreak of new coronavirus pneumonia, analyze the hospitalization,and provide a basis for prevention strategies and treatment plan. Methods We collected the information about residence history and exposure risks by onsite epidemiological investigation, and collected clinical treatment-related data, used statistical software for mapping and analysis. Results The incubation period of the indicated case was 15 days, and the incubation period of the remaining four family members were 1-15 days. The indicated case as an asymptomatic patient had infectious succession within 4-6 days after infection,and four family members were infected one after another. The indicated case carried the virus for more than 8 days, and the remaining 4 patients ranged from 2 to 31 days. The duration of symptoms was 5-20 days of all 5 patients, and the number of CT examinations during hospitalization was 4-10 times. The pulmonary inflammation was improved on the third day of hospitalization at best. In the early stage of the disease, only one patient had leukopenia and lymphopenia decreased. The interval between onset and hospitalization was 1-10 days for five family members, with an average hospitalization time of 23.4 days. Conclusion The asymptomatic infected patient of COVID-19 plays a key role in the family convergence epidemic transmission. The symptoms are inapparent, so it is difficult to find in time. It will cause the risk of infection and increase the difficulty of COVID-19 prevention and control.

目的 探讨阿莫西林克拉维酸钾干混悬剂(7:1)联合胸腺肽治疗支气管哮喘合并肺部感染患儿的临床疗效。方法 选取我院支气管哮喘合并肺部感染患儿102例,依照治疗方案不同分为研究组(n=51)、常规组(n=51)。常规组采用M胆碱受体阻断剂联合阿莫西林克拉维酸钾干混悬剂(7:1)治疗,研究组于常规组基础上采用胸腺肽治疗,统计比较两组临床疗效、随访3个月复发率及治疗前后血清炎性因子[白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)]水平、肺功能指标[第1 s用力呼气容积(FEV₁)、第1 s用力呼气容积/用力肺活量(FEV₁/FVC)]。结果 研究组治疗总有效率94.12%高于常规组80.39%(P＜0.05);治疗2周后研究组FEV₁、FEV₁/FVC水平高于常规组,血清IL-6、TNF-α水平低于常规组(P＜0.05);研究组复发率3.70%(1/27)与常规组11.11%(2/18)比较,差异无统计学意义(P＞0.05)。结论 阿莫西林克拉维酸钾干混悬剂(7:1)联合胸腺肽治疗支气管哮喘合并肺部感染患儿疗效显著,可降低患儿炎症反应、改善肺功能。